The activation of Proteinase-Activated Receptor-1 (PAR1) mediates gastric cancer cell proliferation and invasion

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Fujimoto, Daisuke ^a   Hirono, Yasuo ^a   Goi, Takanori ^a   Katayama, Kanji ^a   Matsukawa, Shigeru ^a   Yamaguchi, Akio ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; MESSENGER RNA; NEUTRALIZING ANTIBODY; PROTEIN BCL 2; PROTEINASE ACTIVATED RECEPTOR 1; TENASCIN; THROMBIN; EGFR PROTEIN, HUMAN;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CELL INVASION; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; STOMACH CANCER; TUMOR GROWTH; WESTERN BLOTTING; CANCER INVASION; CELL MOTION; CULTURE MEDIUM; DRUG EFFECT; DRUG POTENTIATION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; NF-KAPPA B; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PAR-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TENASCIN; THROMBIN;

EID: 77955689997     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-443     Document Type: Article

References (38)

1. Prins M, and Otten HMM. Thrombosis and cancer: A short history of Trousseau's syndrome. Thrombosis and Cancer 2004, 1-10. Taylor and Francis London, New York, Lugassy G, Falanga A, Kakkar A, Rickles F.
2. Walz DA, and Fenton JW. The role of thrombin in tumor cell metastasis. Invasion Metastasis 1994, 14:303-308.
3. Nierodzik ML, and Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006, 10:355-362. 10.1016/j.ccr.2006.10.002, 17097558.
4. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005, 3:1800-1814. 10.1111/j.1538-7836.2005.01377.x, 16102047.
5. Hollenberg MD, Compton SJ. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 2002, 54:203-17. 10.1124/pr.54.2.203, 12037136.
6. Ossovskaya VS, Bunnett NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004, 84:579-621. 10.1152/physrev.00028.2003, 15044683.
7. Steinhoff M, Buddenkotte J, Hollenberg MD, et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 2005, 26:1-43. 10.1210/er.2003-0025, 15689571.
8. Ramachandran R, Hollenberg MD. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 2008, 153(Suppl 1):S263-82. 10.1038/sj.bjp.0707507, 2268078, 18059329.
9. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning a potential proteinase activated receptor. Proc Natl Acad Sci USA 1994, 91:9208-12. 10.1073/pnas.91.20.9208, 44781, 7937743.
10. Even-Ram S, Uziely B, Bar-Shavit R, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998, 4:909-914. 10.1038/nm0898-909, 9701242.
11. Even-Ram SC, Maoz M, Bar-Shavit R, et al. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. J Biol Chem 2001, 276:10952-10962. 10.1074/jbc.M007027200, 11278329.
12. Lafleur MA, Hollenberg MD, Atkinson SJ, Knäuper V, Murphy G, Edwards DR. Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem J 2001, 357:107-115. 10.1042/0264-6021:3570107, 1221933, 11415441.
13. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003, 194:1-11. 10.1016/S0304-3835(02)00699-7, 12706853.
14. Bissell MJ, Radisky D. Putting tumors in context. Nat Rev Cancer 2001, 1:46-54. 10.1038/35094059, 11900251.
15. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174. 10.1038/nrc745, 11990853.
16. López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007, 7:800-808. 10.1038/nrc2228, 17851543.
17. Matsuoka T, Yashiro M, Sawada T, Ishikawa T, Ohira M, Hirakawa K, Chung YS. Effect of a matrix metalloproteinase inhibitor on a lymph node metastatic model of gastric cancer cells passage by orthotopic implantation. J Exp Clin Cancer Res 2001, 20:213-218.
18. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kulipulos A. PAR1 is a matrix metalloproteinase-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005, 120:303-313. 10.1016/j.cell.2004.12.018, 15707890.
19. Darmoul D, Gratio V, Devaud H, Peiretti F, Laburthe M. Activation of Proteinase-Activated Receptor 1 promotes human colon cancer proliferation through Epidermal Growth Factor Receptor transactivation. Mol Cancer Res 2004, 2:514-522.
20. Bergmann S, Junker K, Henklein P, Hollenberg MD, Settmacher U, Kaufmann R. PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration. Oncol Rep 2006, 15:889-893.
21. Tantivejkul K, Lodberg DR, Pienta JK, et al. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 2005, 96:641-652. 10.1002/jcb.20533, 16052512.
22. Fujimoto D, Hirono Y, Goi T, Katayama K, Yamaguchi A. Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. Anticancer Res 2008, 28:847-854.
23. De Wever O, Nguyen QD, Van Hoorde L, Bracke M, Bruyneel E, Gespach C, Mareel M. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 2004, 18:1016-1018.
24. Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Granziano M. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1-methlethyl-)phenyl]methyl}-7H-pyrrolo[3,2-f] quinazoline-1,3-diamine (SCH79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 2000, 60:1425-1434. 10.1016/S0006-2952(00)00460-3, 11020444.
25. Natarajan K, Singh S, Bruke TR, Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci USA 1996, 93:9090-9095. 10.1073/pnas.93.17.9090, 38600, 8799159.
26. Mann KG, Brummel K, Butenas S. What is all that thrombin for?. J Thromb Haemost 2003, 1:1504-1524. Review, 10.1046/j.1538-7836.2003.00298.x, 12871286.
27. Kawabata A, Saifeddine M, Al-Ani B, Leblond L, Hollenberg MD. Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands. J Pharmacol Exp Ther 1999, 288:358-370.
28. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaroonson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987, 47:3239-3245.
29. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 1999, 38:4572-4585. 10.1021/bi9824792, 10194379.
30. Ishii K, Hein L, Kobilka B, Coughlin SR. Kinetics of thrombin receptor cleavage on intact cells-relation to signaling. J Biol Chem 1993, 268:9780-9786.
31. Vouret-Craviari V, Van Obberghen-Schilling E, Scimeca JC, Van Obberghen E, Pouysségur J. Differential activation of p44mapk (ERK1) by alpha-thrombin and thrombin-receptor peptide agonist. Biochem J 1993, 289:209-214. 1132151, 8380983.
32. Hollenberg MD, Mokashi M, Leblond L, DiMaio J. Synergistic actions of a thrombin-derived synthetic peptide and a thrombin receptor-activating peptide in stimulating fibroblasts mitogenesis. J Cell Physiol 1996, 169:491-496. 10.1002/(SICI)1097-4652(199612)169:3<491::AID-JCP9>3.0.CO;2-J, 8952698.
33. Mari B, Imbert V, Auberger P, et al. Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. J Biol Chem 1994, 269:8517-23.
34. Swindle CS, Tran KT, Johnson TD, Banerjee P, Mayes AM, Griffith L, Wells A. Epidermal growth factor (EGF)-like repeats of human Tenascin-C a ligands for EGF receptor. J Cell Biol 2001, 154:459-468. 10.1083/jcb.200103103, 2150768, 11470832.
35. Ohno Y, Izumi M, Yoshioka K, Ohori M, Yonou H, Tachibana M. Prognostic significance of tenascin-C expression in clear cell renal cell carcinoma. Oncol Rep 2008, 20:511-516. 2008.
36. Maschler S, Grunert S, Danielopol A, Beug H, Wirl G. Enhanced tenascin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumor cells. Oncogene 2004, 23:3622-3633. 10.1038/sj.onc.1207403, 15116096.
37. Emoto K, Yamada Y, Nakajima Y, et al. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 2001, 92:1419-1426. 10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J, 11745218.
38. Orend G, Chiquet-Ehrismann R. Teanscin-C induced signaling in cancer. Cancer Lett 2006, 244:143-163. 10.1016/j.canlet.2006.02.017, 16632194.